84100-54-9

Usage

Uses

Used in Pharmaceutical Synthesis:
4-(Ethylamino)piperidine-4-carboxamide is utilized as a building block in medicinal chemistry for the synthesis of various pharmaceuticals. Its unique structural features make it a versatile component in the creation of new drugs with potential therapeutic applications.
Used in Medicinal Research:
In the field of medicinal research, 4-(ethylamino)piperidine-4-carboxamide is studied for its potential pharmacological properties. It has been investigated for its analgesic effects, which could be beneficial in the development of pain management therapies.
Used in Neurodegenerative Disorder Treatment:
4-(Ethylamino)piperidine-4-carboxamide is also being explored as a potential treatment for neurodegenerative disorders. Its unique properties may contribute to the development of therapies that can slow or halt the progression of such conditions, improving the quality of life for affected individuals.
Used in Drug Development:
The ethylamino group on the piperidine ring of 4-(ethylamino)piperidine-4-carboxamide provides 4-(ethylamino)piperidine-4-carboxamide with properties that are advantageous for drug development. Its potential use in creating new medications with specific therapeutic targets makes it an important compound in the ongoing search for novel treatments for various diseases and conditions.

InChI:InChI=1/C8H17N3O/c1-2-11-8(7(9)12)3-5-10-6-4-8/h10-11H,2-6H2,1H3,(H2,9,12)

Upstream product

• 7440-44-0 pyrographite 
• 1027-91-4 1-benzyl-4-ethylaminopiperidine-4-carboxylic acid amide 

Downstream Products

• 686344-29-6 Otenabant 
• 1365037-14-4 1-{[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl]carbonyl}-4-(ethylamino)piperidine-4-carboxamide 

Relevant academic research and scientific papers

Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4- ethylamino-piperidine-4-carboxylic Acid Amide Hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonist

We report the structure-activity relationships, design, and synthesis of the novel cannabinoid type 1 (CB1) receptor antagonist 3a (CP-945,598). Compound 3a showed subnanomolar potency at human CB1 receptors in binding (Ki= 0.7 nM) and functional assays (K i = 0.12 nM). In vivo, compound 3a reversed cannabinoid agonist-mediated responses, reduced food intake, and increased energy expenditure and fat oxidation in rodents. The endocannabinoid system (ECS a), and speci?cally the cannabinoid type 1 (CB1) receptor, plays a pivotal role in energy homeostasis.1-3 As such, stimulation of the ECS promotes food intake and energy storage and may be chronically overactive in obese subjects.4-7 In contrast, blockade of the CB 1 receptor decreases food intake and increases energy expenditure, leading to a reduction in body weight.8-11 It was hoped that CB 1 ceptor antagonists might provide effective therapy options for the management of metabolic disorders, such as obesity. Unfortunately, several CB1 receptor inverse agonists/antagonists were recently withdrawn from clinical development including the diarylpyrazole rimonabant12 1 (SR141716A) and the acyclic amide taranabant132 (MK-0364). Herein, we describe the design strategies that led to the identi?cation of a series of purine derivatives as CB1 receptor antagonists, and the optimization of PK properties that resulted in the discovery of the orally active 3a (CP-945,598), a novel, potent, and selective CB1 receptor antagonist, recently evaluated in phase 3 clinical trials for weight management.

PYRAZOLE COMPOUNDS HAVING CANNABINOID RECEPTOR (CB1) ANTAGONIZING ACTIVITY

The present invention relates to a pyrazole compound having potent CB1-antagonizing activity, having the following formula [I]: wherein R1 and R2 are the same or different and an optionally substituted aryl group etc., R3 is an alkyl group etc., E is one of the following groups of the formula (i) to (iv): Q1 is a single bond, an alkylene group or a group of the formula: -N(R7)-, R7 is a hydrogen atom or an alkyl group, Q2 is a single bond, an oxygen atom or an alkylene group, R4 is a cycloalkyl group, a group of the formula: -N(R5)(R6) etc., one of R5 and R6 is a hydrogen atom or an alkyl group and the other is an alkyl group, a group of the formula: -N(R8)(R9) etc., D is an oxygen atom etc., RA1 is an amino group etc., RA2 is an optionally substituted aliphatic heterocyclic group, R is an alkyl group optionally substituted by one to three halogen atom(s) etc., one of R8 and R9 is a hydrogen atom or an alkyl group and the other is an alkyl group etc., or a pharmaceutically acceptable salt thereof.

PROCESS FOR PREPARING PURINE COMPOUNDS

A process for preparing compounds of Formula (I) are described herein as well as key intermediates.

CANNABINOID RECEPTOR LIGANDS AND USES THEREOF

Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.

PURINE COMPOUNDS AND USES THEREOF AS CANNABINOID RECEPTOR LIGANDS

Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.

CANNABINOID RECEPTOR LIGANDS AND USES THEREOF

Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.

Cannabinoid receptor ligands and uses thereof

Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.

Cannabinoid receptor ligands and uses thereof

Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.